

















20. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. *Clin Cancer Res* 2012; 18:510-23; PMID:22128301; <http://dx.doi.org/10.1158/1078-0432.CCR-11-1973>.
21. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. *Clin Cancer Res* 2012; 18:1655-62; PMID:22291137; <http://dx.doi.org/10.1158/1078-0432.CCR-11-2890>.
22. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. *Breast Cancer Res Treat* 2012; 134:649-59; PMID:22678161; <http://dx.doi.org/10.1007/s10549-012-2106-5>.
23. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. *Cancer Res* 2010; 70:7970-80; PMID:20798217; <http://dx.doi.org/10.1158/0008-5472.CAN-09-4521>.
24. Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. *Cancer Res* 2012; 72:4796-806; PMID:22987487; <http://dx.doi.org/10.1158/0008-5472.CAN-12-1287>.
25. Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. *Breast Cancer Res Treat* 2012; 135:505-17; PMID:22875744; <http://dx.doi.org/10.1007/s10549-012-2188-0>.
26. Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. *PLoS One* 2012; 7:e46614; PMID:23071597; <http://dx.doi.org/10.1371/journal.pone.0046614>.
27. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. *Cancer Discov* 2012; 2:1036-47; PMID:22915752; <http://dx.doi.org/10.1158/2159-8290.CD-11-0348>.
28. Drew Y, Mulligan EA, Vong W-T, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. *J Natl Cancer Inst* 2011; 103:334-46; PMID:21183737; <http://dx.doi.org/10.1093/jnci/djq509>.
29. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and pre-clinical models for selection of targeted therapies. *J Clin Invest* 2011; 121:2750-67; PMID:21633166; <http://dx.doi.org/10.1172/JCI45014>.
30. Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. *Clin Exp Metastasis* 2008; 25:549-57; PMID:18386134; <http://dx.doi.org/10.1007/s10585-008-9169-z>.
31. McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. *Ann Oncol* 2013; 24:362-; PMID:22967992; <http://dx.doi.org/10.1093/annonc/mds279>.
32. Rani S, Clynes M, O'Driscoll L. Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function. *Clin Chem* 2007; 53:1936-44; PMID:17717131; <http://dx.doi.org/10.1373/clinchem.2007.087973>.